A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, redu
A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.
대표청구항▼
1. A hemostatic powder comprising a hemostatic material, wherein the hemostatic material consists of biocompatible modified starch particles, wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units in the starch, wherein the biocompatible modified sta
1. A hemostatic powder comprising a hemostatic material, wherein the hemostatic material consists of biocompatible modified starch particles, wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units in the starch, wherein the biocompatible modified starch particles are non-porous and substantially devoid of a microporous surface, wherein the powder has an adhesiveness sufficient to form a starch-blood coagulation matrix upon contacting a wound tissue. 2. The hemostatic powder of claim 1, wherein the biocompatible modified starch exhibits a water absorbency capacity that is at least 1 times its own weight. 3. The hemostatic powder of claim 1, wherein the biocompatible modified starch exhibits a water absorbency capacity that is 2-500 times its own weight. 4. The hemostatic powder of claim 1, wherein the biocompatible modified starch exhibits a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C. 5. The hemostatic powder of claim 1, wherein the hemostatic powder is degradable by amylase. 6. The hemaostatic powder of claim 1, wherein the hemostatic powder exhibits an adhesion Work Index at maximum water absorption at room temperature exceeding 40 g sec (100% saturation) when assayed with a texture analyzer (Stable Micro System, Model TA-XT plus) together with a backforward extrusion probe (A/BE) or a cylindrical probe (P36R). 7. The hemostatic powder of claim 1, wherein the hemostatic powder is free of polyethylene glycol. 8. The hemostatic powder of claim 1, wherein the biocompatible modified starch contains a modified glucose unit of the formula: 9. The hemostatic powder of claim 1, wherein the biocompatible modified starch is carboxymethyl starch. 10. The hemostatic powder of claim 1, wherein the biocompatible modified starch is hydroxyethyl starch. 11. The hemostatic powder of claim 1, wherein the biocompatible modified starch is cross-linked. 12. The hemostatic powder of claim 1, wherein the biocompatible modified starch is not cross-linked. 13. The hemostatic powder of claim 1, wherein the biocompatible modified starch exhibits a molecular weight of at least 15,000 daltons. 14. The hemostatic powder of claim 1, wherein the biocompatible modified starch particles have a grain diameter of 1 to 1000 μm. 15. The hemostatic powder of claim 1, wherein the biocompatible modified starch particles are pre-gelatinized modified starch. 16. The hemostatic powder of claim 1, wherein the biocompatible modified starch particles are composite modified starch. 17. The hemostatic powder of claim 1, wherein the hemostatic powder further comprises one or more of biocompatible carboxymethyl cellulose, chitosan, sodium alginate, and a coagulant. 18. The hemostatic powder of claim 1, wherein the powder further comprises an antibiotic.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (27)
Ganslaw ; Stuart H. ; Katz ; Howard G., Absorbent composition of matter.
Kwon Sang Gi,KRX ; Cho Yang Rae,KRX ; Park Chan Hun,KRX ; Ko Chul Jong,KRX, Carboxymethyl-etherified starch derivatives and process for preparing the same.
Jy, Wenche; Jimenez, Joaquin J.; Horstmann, Lawrence L.; Ahn, Yeon S.; Ahn, Eugene, Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders.
Errede Louis A. (North Oaks MN) Stoesz James D. (St. Paul MN) Winter ; deceased George D. (late of St. Paul MN by Jenny Upton ; personal representative), Composite wound dressing.
Abe,Yoshihiko; Anzai,Takao, Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition, and medical treatment material.
de Belder Anthony N. (Uppsala SEX) Mlson Thomas (Uppsala SEX), Method of preventing adhesion between body tissues, means for preventing such adhesion, and process for producing said m.
Barrington James E. (Woburn MA) Williams David L. (Reading MA) Hitchcock Charles J. (Cambridge MA) Mullins Thomas J. (Woburn MA), Powder blower device.
Terakura Seiji (Ikoma JPX) Maeda Toyoyuki (Kawachinagano JPX), Powdered medicament-mixed gas injecting apparatus and powdered medicament-mixed gas injecting nozzle to be connected to.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.